What Is Zepbound Used For? FDA-Approved Uses, Doses, and Expected Results

Key Takeaways

• Zepbound (tirzepatide) is FDA-approved for chronic weight management in adults with obesity (BMI 30+) or overweight (BMI 27+) plus a weight-related condition.
• In December 2024 the FDA expanded approval to include moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity.
• Average weight loss in the SURMOUNT-1 trial was 20.9% at the highest dose over 72 weeks.
• It is given as a once-weekly subcutaneous injection in doses from 2.5 mg to 15 mg, with mandatory titration to limit side effects.
• Zepbound is not approved for type 2 diabetes. The same molecule (tirzepatide) is sold as Mounjaro for diabetes.

Direct answer (40-60 words)

Zepbound is FDA-approved for two uses: chronic weight management in adults with obesity or overweight plus a weight-related health condition, and moderate-to-severe obstructive sleep apnea in adults with obesity. The active ingredient is tirzepatide. It is given as a once-weekly subcutaneous injection at doses from 2.5 mg to 15 mg.

Table of contents

1. The short answer
2. Approved use 1: chronic weight management
3. Approved use 2: obstructive sleep apnea
4. How Zepbound works (mechanism)
5. The dose schedule
6. Expected results from the SURMOUNT trials
7. Who qualifies for a prescription
8. Off-label and investigational uses
9. Zepbound vs Mounjaro: what is the difference
10. FAQ
11. Sources
12. Footer disclaimers

Approved use 1: chronic weight management

The FDA approved Zepbound for chronic weight management on November 8, 2023. The approved indication reads: as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity (BMI 30 kg/m² or higher) or overweight (BMI 27 kg/m² or higher) in the presence of at least one weight-related comorbid condition such as hypertension, dyslipidemia, type 2 diabetes mellitus, obstructive sleep apnea, or cardiovascular disease.

The approval was based primarily on the SURMOUNT-1 trial, a 72-week randomized placebo-controlled study of 2,539 adults with obesity but without diabetes. Average weight loss at week 72:

Dose	Mean weight loss	Percent of patients losing 5%+
Placebo	3.1%	35%
Tirzepatide 5 mg	15.0%	85%
Tirzepatide 10 mg	19.5%	89%
Tirzepatide 15 mg	20.9%	91%

(Jastreboff et al., NEJM 2022)

The trial also showed reductions in waist circumference, blood pressure, fasting insulin, and triglycerides. Tirzepatide is currently the most effective approved weight-loss medication by absolute percentage.

Approved use 2: obstructive sleep apnea

In December 2024 the FDA expanded Zepbound's label to include moderate-to-severe obstructive sleep apnea in adults with obesity. This was the first time a medication received approval specifically for OSA.

The approval was based on the SURMOUNT-OSA trial, which enrolled adults with moderate-to-severe OSA and obesity. Patients were studied with and without positive airway pressure (PAP) therapy. After 52 weeks:

• Patients on tirzepatide reduced their apnea-hypopnea index (AHI, the standard measure of sleep apnea severity) by 25 to 30 events per hour, compared with 5 to 6 events per hour reduction on placebo.
• About 50% of patients on tirzepatide met criteria for OSA remission or significant improvement.
• Body weight reductions paralleled the SURMOUNT-1 results, around 18% to 20% at week 52.

(Malhotra et al., NEJM 2024)

The approval is significant because OSA in obesity is partly driven by airway fat and weight. Reducing both directly addresses the mechanical cause. Many patients on PAP therapy were able to reduce or discontinue their device after 52 weeks of tirzepatide.

The OSA indication does not change the dose schedule. The same titration protocol applies.

How Zepbound works (mechanism)

Zepbound's active ingredient, tirzepatide, is the first dual-receptor agonist approved in the United States. It activates two receptors at the same time:

1. GLP-1 receptors. Glucagon-like peptide-1 is a gut hormone released after meals. Activating its receptor triggers insulin release, slows gastric emptying, and reduces appetite signals in the brain. Single-receptor GLP-1 agonists like semaglutide have been used since 2017.

1. GIP receptors. Glucose-dependent insulinotropic polypeptide is a second gut hormone with overlapping but distinct effects, including roles in fat metabolism and appetite regulation.

The dual-receptor approach appears to produce more weight loss than single-receptor GLP-1 agents. The exact reason is still being studied, but the SURMOUNT-1 vs STEP 1 comparison shows roughly 5 to 8 percentage points more weight loss on tirzepatide than semaglutide at top doses.

The downstream effects most patients notice:

• Earlier and longer satiety after meals
• Reduced food cravings, especially for high-calorie processed foods
• Slower stomach emptying (which is why nausea is the most common side effect)
• Lower fasting glucose and improved insulin sensitivity

Zepbound is given by subcutaneous injection once weekly because tirzepatide has a half-life of about 5 days. Daily dosing is not required.

The dose schedule

Zepbound comes in single-use auto-injector pens at six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Patients start at 2.5 mg and step up in 4-week increments to limit side effects.

The standard titration schedule per the prescribing information:

Weeks	Dose	Notes
1-4	2.5 mg weekly	Initiation dose; not a therapeutic dose
5-8	5 mg weekly	First therapeutic dose
9-12	7.5 mg weekly	Optional intermediate step
13-16	10 mg weekly	Common maintenance dose
17-20	12.5 mg weekly	Optional intermediate step
21+	15 mg weekly	Maximum dose

Many patients stop escalating at 5 mg, 10 mg, or 12.5 mg if those doses produce adequate weight loss without intolerable side effects. There is no clinical rule that says you must reach 15 mg.

If side effects from a dose are intolerable, the prescribing information allows staying longer at the current dose or stepping down to the previous dose. Patients should not skip doses or extend the interval beyond a week unless directed by their provider.

Expected results from the SURMOUNT trials

The SURMOUNT trial program studied tirzepatide across multiple populations. Headline results:

SURMOUNT-1 (obesity without diabetes): 20.9% mean weight loss at 15 mg over 72 weeks (Jastreboff et al., NEJM 2022).

SURMOUNT-2 (obesity with type 2 diabetes): 14.7% mean weight loss at 15 mg over 72 weeks. Slightly less than SURMOUNT-1 because diabetes typically blunts weight-loss response (Garvey et al., Lancet 2023).

SURMOUNT-3 (obesity, with intensive lifestyle pre-treatment): 21.1% additional weight loss on tirzepatide after 12 weeks of intensive lifestyle, vs 3.3% additional on placebo (Wadden et al., Nat Med 2023).

SURMOUNT-4 (continued weight loss vs withdrawal): Patients who continued tirzepatide kept losing weight (extra 5.5%); patients switched to placebo regained about 14% of their lost weight (Aronne et al., JAMA 2024).

SURMOUNT-OSA (obstructive sleep apnea): AHI reduction of 25 to 30 events per hour at 52 weeks (Malhotra et al., NEJM 2024).

The pattern across trials is consistent: tirzepatide produces large weight losses, but the losses are durable only if treatment continues. Withdrawal leads to regain.

For patients on Zepbound, a reasonable mental model:

• Months 1 to 3: 5% to 8% weight loss, side effects most prominent
• Months 4 to 6: 10% to 14% weight loss, side effects fading
• Months 7 to 12: 15% to 20% weight loss, plateau approaching
• Beyond 12 months: maintenance, with small additional loss possible

Who qualifies for a prescription

The FDA-approved indication for chronic weight management requires:

• BMI 30 kg/m² or higher (obesity), OR
• BMI 27 kg/m² or higher (overweight) PLUS at least one weight-related condition

Qualifying weight-related conditions include hypertension, dyslipidemia, type 2 diabetes, obstructive sleep apnea, cardiovascular disease, and similar comorbidities. The OSA-specific indication requires moderate-to-severe OSA and obesity (BMI 30+).

Patients who do not qualify under FDA labeling:

• BMI under 27 with no comorbidity
• BMI 27 to 29 with no qualifying comorbidity
• Personal or family history of medullary thyroid carcinoma or MEN-2 (contraindicated)
• History of severe pancreatitis
• Pregnancy or planned conception within 2 months
• Severe gastroparesis or active eating disorder

Insurance coverage often requires a higher BMI threshold (typically 30+) and documented prior failure of lifestyle interventions. Coverage is inconsistent across plans, which is why many patients use cash-pay options or compounded alternatives.

Internal links: see /articles/getting-started/zepbound-eligibility-checklist/ and /articles/cost-and-insurance/zepbound-insurance-coverage/ for details on qualification and cost.

Off-label and investigational uses

Tirzepatide is being studied or used off-label for several conditions. None of these uses is FDA-approved as of April 2026.

Type 2 diabetes. The same molecule is approved as Mounjaro for type 2 diabetes. Some providers prescribe Zepbound to diabetic patients when Mounjaro is unavailable. The molecule is identical.

Cardiovascular outcomes. SURPASS-CVOT is an ongoing cardiovascular outcomes trial. Results are expected in 2026 or 2027 and may eventually support a cardiovascular indication.

Heart failure with preserved ejection fraction (HFpEF). SUMMIT trial showed tirzepatide reduced HFpEF events and improved symptoms in patients with obesity and HFpEF (Packer et al., NEJM 2024). An indication may follow.

Non-alcoholic steatohepatitis (NASH/MASH). Tirzepatide has shown improvement in liver fat and inflammation in early studies. Trials are ongoing.

Polycystic ovary syndrome (PCOS). Used off-label by some endocrinologists for PCOS-related insulin resistance and weight gain. No FDA approval.

Substance use disorders. Animal data and small human studies suggest GLP-1 agonists may reduce alcohol craving and tobacco use. Clinical trials are early-stage.

Off-label use is legal but is not the same as FDA-approved. The trial evidence varies by use case.

Zepbound vs Mounjaro: what is the difference

Zepbound and Mounjaro contain the same active ingredient (tirzepatide), made by the same manufacturer (Eli Lilly), at the same doses (2.5 mg through 15 mg), in similar pen devices. The differences are regulatory, not chemical.

Feature	Zepbound	Mounjaro
Active ingredient	Tirzepatide	Tirzepatide
FDA approval	Obesity, OSA in obesity	Type 2 diabetes
Pen design	Slightly different cartridge color/labeling	Different cartridge color/labeling
Dose strengths	2.5 to 15 mg	2.5 to 15 mg
Manufacturer	Eli Lilly	Eli Lilly
Insurance coverage	Often weight-loss benefit	Usually diabetes benefit

The reason for two brands is that insurance companies cover them differently. Many plans exclude weight-loss medications but cover diabetes medications. Splitting tirzepatide into two brands lets providers prescribe the molecule under whichever indication matches the patient's coverage and condition.

If a patient has both type 2 diabetes and obesity, either brand can be appropriate. The choice usually comes down to which one their insurance covers.

FAQ

What is Zepbound used for?

Zepbound is FDA-approved for chronic weight management in adults with obesity or overweight plus a weight-related condition, and for moderate-to-severe obstructive sleep apnea in adults with obesity. The active ingredient is tirzepatide.

Is Zepbound the same as Ozempic?

No. Zepbound contains tirzepatide. Ozempic contains semaglutide. They are different molecules with different mechanisms (tirzepatide hits two receptors, semaglutide hits one). Zepbound also produces more weight loss in head-to-head comparisons.

Is Zepbound approved for diabetes?

No. Zepbound is not approved for type 2 diabetes. The same molecule is sold as Mounjaro for diabetes. Some providers prescribe Zepbound off-label for diabetes if Mounjaro is unavailable, but the FDA-approved diabetes brand is Mounjaro.

How much weight will I lose on Zepbound?

Average weight loss in SURMOUNT-1 was 20.9% at the highest dose over 72 weeks. Real-world results vary widely. About 9 in 10 patients on the higher doses lose at least 5% of their body weight. About half lose 20% or more.

How is Zepbound administered?

Zepbound is given as a once-weekly subcutaneous injection using a single-use auto-injector pen. Common injection sites are the abdomen, thigh, or upper arm. Rotate sites weekly.

How long does Zepbound take to work?

Most patients notice reduced appetite within the first 1 to 2 weeks. Measurable weight loss usually starts in week 2 to 4. Full results take 6 to 12 months as the dose escalates and the body adapts.

Do I have to take Zepbound forever?

For lasting weight loss, most patients need to continue treatment. The SURMOUNT-4 trial showed that patients who stopped after the loss phase regained about 14% of their body weight. Discontinuing Zepbound is similar to discontinuing any chronic medication: the underlying condition often returns.

What is the maximum dose of Zepbound?

The maximum approved dose is 15 mg once weekly. Many patients reach effective weight loss at 5 mg, 10 mg, or 12.5 mg and do not need to escalate further.

Is Zepbound covered by insurance?

Coverage varies. Many commercial plans now cover Zepbound for the OSA indication and for weight management with prior authorization. Medicare does not cover weight-loss medications under Part D as of 2026. The OSA indication may open Medicare coverage in some cases.

What happens if I miss a Zepbound dose?

If you remember within 4 days of the missed dose, take it and resume your weekly schedule. If more than 4 days have passed, skip the missed dose and take the next one on your usual day. Never take two doses within 3 days of each other.

Can I drink alcohol on Zepbound?

Small amounts are usually tolerated. Alcohol increases nausea and may worsen reflux. Many patients find their tolerance for alcohol drops on tirzepatide. Heavy drinking is discouraged because it raises pancreatitis risk.

Is compounded tirzepatide the same as Zepbound?

No. Zepbound is FDA-approved and made by Eli Lilly under cGMP standards. Compounded tirzepatide is prepared by a state-licensed compounding pharmacy in response to an individual prescription and is not FDA-approved. They are not interchangeable, though the active ingredient is the same molecule when sourced from a reputable U.S. compounder.

Related guides

• What Is Ozempic Used For? FDA-Approved Uses, Off-Label Uses, and How It Works
• What Is Semaglutide Used For: FDA-Approved Uses, Off-Label Applications, and the Clinical Evidence Behind Each
• What Is Rybelsus Used For? FDA-Approved Indications, Off-Label Uses, and the Oral Semaglutide Question
• What Is Mounjaro Used For? Approved Uses, Off-Label Uses, and What's Inside the Pen
• What Is Wegovy Used For? Approved Uses, Eligibility, and What to Expect
• What Is Tirzepatide Used For: The Two FDA Approvals, Four Off-Label Uses, and How the Mechanism Drives Each One
• Tool: dosage calculator

Sources

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216.
2. Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402:613-626.
3. Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Nat Med. 2023;29:2909-2918.
4. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331:38-48.
5. Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity (SURMOUNT-OSA). N Engl J Med. 2024;391:1193-1205.
6. Packer M, Zile MR, Kramer CM, et al. Tirzepatide for heart failure with preserved ejection fraction and obesity (SUMMIT). N Engl J Med. 2024.
7. U.S. Food and Drug Administration. Zepbound (tirzepatide) Prescribing Information. Eli Lilly and Company. 2024.
8. U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea. December 2024.
9. American Diabetes Association. Standards of Care in Diabetes. 2026.
10. Endocrine Society. Pharmacological Management of Obesity Clinical Practice Guideline. 2024.
11. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Prescription Medications to Treat Overweight and Obesity. 2025.
12. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385:503-515.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly.